GlassScriptPhysician profile
Carl B Rountree
NPI 1538185814
$2,683.75
in general payments reported to CMS, 2019-2025
15 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $558 · 2020: $1,127 · 2021: $601 · 2022: $398.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,061.41 | 2019-2022 | |
| Ucb, INC. | $354.36 | 2020-2022 | |
| Mayne Pharma Commercial LLC | $329.01 | 2019-2020 | |
| Lilly USA, LLC | $245.28 | 2019-2022 | |
| Genzyme Corporation | $201.59 | 2020-2021 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $126.39 | 2019-2020 | |
| Leo Pharma INC. | $102.57 | 2020-2021 | |
| Abbvie INC. | $102.01 | 2019-2021 | |
| Regeneron Healthcare Solutions, INC. | $47.23 | 2020-2021 | |
| Medimetriks Pharmaceuticals, INC. | $27.85 | 2020 | |
| Taro Pharmaceuticals USA, INC. | $23.85 | 2019 | |
| Dermira, INC. | $17.03 | 2020 | |
| Galderma Laboratories, L.P. | $15.53 | 2021 | |
| Amgen INC. | $15.00 | 2020 | |
| Almirall LLC | $14.64 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Carl Rountree listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.